Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma
Christopher Rushton(Simon Fraser University), Ryan D. Morin(Simon Fraser University), Lois E. Shepherd(Ontario Institute for Cancer Research), Laura K. Hilton(BC Cancer Agency), Aixiang Jiang(Simon Fraser University), David W. Scott, Joseph M. Connors, Matthew C. Cheung(Simon Fraser University), Nathalie A. Johnson(Genomics (United Kingdom)), Kirstie L.S. Cleary(University of Southampton), Kevin Bushell(Simon Fraser University), Koren K. Mann(Jewish General Hospital), Krysta M. Coyle(Simon Fraser University), Christian Steidl(Spinal Cord Injury BC), Miguel Alcaide(Consejo Superior de Investigaciones Científicas), Michael Crump(Princess Margaret Cancer Centre), Ryan N. Rys(McGill University), Marco A. Marra(BC Cancer Agency), Mark S. Cragg(University of Southampton), John Kuruvilla(Princess Margaret Cancer Centre), Sarah E. Arthur(Simon Fraser University), Scott R. Daigle(Epizyme (United States)), Sarit Assouline(Jewish General Hospital), Neil R. Michaud(Epizyme (United States)), Jordan Davidson(Simon Fraser University), Nicole Thomas(Simon Fraser University), Stephen Yu(Simon Fraser University), Michael D. Jain(Moffitt Cancer Center)
Cited by 120
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k
The NIH Roadmap Epigenomics Mapping Consortium
|Nature Biotechnology|2010|2k